Don't shut down the pharmacy of the developing world
handsoff.msf.org
handsoff.msf.org
This way we don't have to worry about new drug discovery drying up because of lack of profits, while at the same time we have a way to allow government funding for actual drugs that could be provided at low cost.
I think this private-public competition will provide both innovation and low prices in the long term.
But maybe government could be more return-on-investment friendly for the citizens who pay taxes and re-route some of that research founds into actually developing the end user drugs. At the same time they could create legal barriers for private pharma from using any tax funded pharma research. That would create some loud screams from the pharma lobby, and we would finally be able to say how valuable the patent supported pharma industry really is. I doubt however we will ever see such day, and patent supported pharma will continue to claim the glory while tax payers silently pays double for medicine. First through taxes and then a second time through the expensive drug prices in the pharmacy.
I tend to view private pharma, as it exists today, as a leech on society, at best. Perhaps destroying it and making it pay it's own way entirely would be for the best.
Yes, in the past, private companies did real work and it was beneficial. But, mostly, they seem to invent cures for problems that get blown way out of proportion thru marketing directly to the public (restless leg syndrome? really?).
At a minimum, let doctors become the filter thru which medicine is prescribed, and put a very heavy penalty in place for pay-to-subscribe.
While the for-profit system has some flaws, at least their motivations are relatively straightforward and when there's a reason to change their policies by discounting or even giving things away free, they can choose to.
If the government tried to do that, it would turn into a multi-month (year?) debate before anything would be done.
I'll take the mythical use of pharma research as a political weapon over the all too real Martin Shkreli phenomenon.
Not all political setups devolve into the chaos experienced by the US.
The US could be unique in that compulsory licensing laws and aggressive patent invalidation don't work--there aren't many desirable foreign patents to invalidate or inventions to compel licensure.
To be fair, the top two baldness treatments were side-effects of drugs aimed at curing more "serious" conditions.
Rogaine was first developed as a cure for ulcers. That didn't work, but the researchers noticed that it served as a vasodilator and it was sold as a treatment for high blood pressure. That didn't work out either, but researchers noticed one weird side effect... [1]
Same for Propecia / Proscar, which started out targeted at prostate growth. It's effective at controlling prostate growth and in this case researchers realized that the same hormone channel that controls prostates (DHT) also affects hair loss. They then set out to find another way to monetize the existing drug.
Attempts to target baldness only have struggled (there has been a line of smaller companies trying to get baldness-only drugs through trials, which have mostly failed.)
[1] https://en.wikipedia.org/wiki/Minoxidil#History [2] https://en.wikipedia.org/wiki/Finasteride#History
This barrier to entry may decrease as biological models become cheaper and more accessible, but even as a hopeful bioinformatician, I am skeptical of this happening in the near term (10-15 years).
Even if a government research department was 20% less effective than an equivalent private sector research department (which I strongly doubt; they're probably equivalent), it would still be more cost effective. Pharma marketing budgets are titanic and that's an epic waste of money.
Pfizer: $7,690 million R&D, $14,809 million SGA
Merck: $6,704 million R&D, $10,313 million SGA
AstraZeneca: $5,997 million R&D, $9,951 million SGA
If he actually said that, it was a pretty stupid thing to say. Somewhat effective treatments against malaria have been available to western medicine since the 1600s (quinine bark) and pretty good synthetics since the early 20th century.
The first treatment for baldness that was even moderately effective (minoxidil) didn't even enter use until the late 1980s, and note (this is key) that its anti-baldness action was a serendipitous side effect -- the drug was originally developed for high blood pressure, not baldness.
Same thing with the other common whipping boy, V%%%%%a (not spelling it out lest it trip a spam filter). It was for high blood pressure and angina.
http://www.independent.co.uk/news/world/americas/bill-gates-...
“Our priorities are tilted by marketplace imperatives,” he said at the Royal Academy of Engineering’s Global Grand Challenges Summit.
“The malaria vaccine in humanist terms is the biggest need, but it gets virtually no funding. If you are working on male baldness or other things you get an order of magnitude more research funding because of the voice in the marketplace than something like malaria.”
And if you think that is stupid, here is what others say:
Mr Gates’ complaint is echoed by the Global Forum for Health Research, which estimates that only 10 per cent of worldwide expenditure on health research is devoted to the problems that afflict 90 per cent of the world’s population – the so-called 10/90 gap. Malaria is estimated to have killed 660,000 people in 2010, most of them African children. About half of the world’s population is at risk. The transmission of the disease can be controlled by distributing cheap mosquito nets treated with insecticides. Research into a vaccine for the disease has so far failed to yield any results.
2) "Research into a vaccine for the disease has so far failed to yield any results."
Maybe it gets "virtually no funding" because it's seen as an insurmountable problem given the current state of the art? The malaria organism is an entirely different kind of life form from the organisms for which human vaccines have historically been effective. It's a protozoan, not a bacterium or virus. As far as I know (and Google seems to confirm this) there is no vaccine for any human disease caused by protozoa.
Edit: this article describes some of the hurdles. It's not just funding.
None of those treatments are vaccines.
I'm not sure what makes stating those facts "deft maneuvering".
Open source reduces transaction costs and it also reduces startup costs.
http://www.fool.com/investing/general/2016/04/30/the-cost-of...
Also - read my link!
I hear government spending on research as part of the defense department is super effective.
Maybe a sarcastic comment isn't the most effective means of communication. But given the quality of the root comment I felt it appropriate.
Here. Let me paste a blurb by Richard Posner from An Economic Analysis of Copyright Law. Copyright law is not the same as patent law, of course. But the balance being sought is much the same.
"A distinguishing characteristic of intellectual property is its "public good" aspect. While the cost of creating a work subject to copyright protection—for example, a book, movie, song, ballet, lithograph, map, business directory, or computer software program—is often high, the cost of reproducing the work, whether by the creator or by those to whom he has made it available, is often low. And once copies are available to others, it is often inexpensive for these users to make additional copies. If the copies made by the creator of the work are priced at or close to marginal cost, others may be discouraged from making copies, but the creator’s total revenues may not be sufficient to cover the cost of creating the work. Copyright protection—the right of the copyright’s owner to prevent others from making copies—trades off the costs of limiting access to a work against the benefits of providing incentives to create the work in the first place. Striking the correct balance between access and incentives is the central problem in copyright law. For copyright law to promote economic efficiency, its principal legal doctrines must, at least approximately, maximize the benefits from creating additional works minus both the losses from limiting access and the costs of administering copyright protection."
Your follow-up post is another non-sequitur